HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chlorprothixene (taractan) in post-herpetic neuralgia and other severe chronic pains.

Abstract
Two trials of chlorprothixene were carried out, mainly on patients with moderate to severe post-herpetic neuralgia. When the drug was given as 50 mg b.d. to outpatients, unpleasant side-effects were more important than slight effects in alleviating pain. When the drug was given as 50 mg 6 hourly to inpatients for 5 days only, there was alleviation of constant chronic pain in a third of the patients; the effect is still lasting over a period of months in a few patients. The side-effects during the course of treatment are prominent. It is concluded that the drug is worth trying in the course recommended by Farber and Burks [1] when other means of controlling postherpetic neuralgia have failed. It would be best to give the course only to inpatients.
AuthorsP W Nathan
JournalPain (Pain) Vol. 5 Issue 4 Pg. 367-371 (Dec 1978) ISSN: 0304-3959 [Print] United States
PMID368703 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
Chemical References
  • Chlorprothixene
Topics
  • Chlorprothixene (adverse effects, therapeutic use)
  • Clinical Trials as Topic
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Herpes Zoster (complications)
  • Humans
  • Neuralgia (drug therapy)
  • Pain, Intractable (drug therapy)
  • Phantom Limb (drug therapy)
  • Reflex Sympathetic Dystrophy (drug therapy)
  • Syringomyelia (drug therapy)
  • Thalamus (physiopathology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: